相似文献
1
Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change.
Ann Rheum Dis. 2005 Feb;64(2):179-82. doi: 10.1136/ard.2003.018457. Epub 2004 Jul 29.
2
3
4
Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference.
Arthritis Rheum. 2002 Apr;46(4):913-20. doi: 10.1002/art.10190.
5
Robustness and generalizability of smallest detectable difference in radiological progression.
J Rheumatol. 2001 Apr;28(4):911-3.
6
Radiography as primary outcome in rheumatoid arthritis: acceptable sample sizes for trials with 3 months' follow up.
Ann Rheum Dis. 2004 Nov;63(11):1413-8. doi: 10.1136/ard.2003.014043. Epub 2004 Mar 22.
7
Precision of Larsen grading of radiographs in assessing progression of rheumatoid arthritis in individual patients.
Ann Rheum Dis. 1990 May;49(5):286-9. doi: 10.1136/ard.49.5.286.
8
Classifying structural joint damage in rheumatoid arthritis as progressive or nonprogressive using a composite definition of joint radiographic change: a preliminary proposal.
Arthritis Rheum. 2004 Apr;50(4):1083-96. doi: 10.1002/art.20270.
9
Modified sharp method: factors influencing reproducibility and variability.
Semin Arthritis Rheum. 2001 Dec;31(3):176-90. doi: 10.1053/sarh.2001.28304.
10
Development and validation of a new radiographic scoring system to evaluate bone and cartilage destruction and healing of large joints with rheumatoid arthritis: ARASHI (Assessment of rheumatoid arthritis by scoring of large joint destruction and healing in radiographic imaging) study.
Mod Rheumatol. 2013 Nov;23(6):1053-62. doi: 10.1007/s10165-012-0823-6. Epub 2013 Apr 27.
引用本文的文献
1
Early rheumatoid arthritis, two distinctive structural damage patterns revealed by MRI: an 8-year longitudinal study.
Eur Radiol. 2025 Mar 18. doi: 10.1007/s00330-025-11493-5.
2
Effects of Secukinumab on Enthesiophyte and Erosion Progression in Psoriatic Arthritis: A One-Year Double-Blind, Randomized, Placebo-Controlled Trial Using High-Resolution Peripheral Quantitative Computed Tomography.
Arthritis Rheumatol. 2025 Aug;77(8):1015-1025. doi: 10.1002/art.43154. Epub 2025 Apr 23.
3
Routine radiographs of hands and feet do not have diagnostic or prognostic value in patients with clinically suspect arthralgia: a large longitudinal study.
RMD Open. 2024 Nov 12;10(4):e004966. doi: 10.1136/rmdopen-2024-004966.
4
Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate.
Rheumatology (Oxford). 2025 Apr 1;64(4):1661-1671. doi: 10.1093/rheumatology/keae486.
5
The design of a sample rapid magnetic resonance imaging (MRI) acquisition protocol supporting assessment of multiple articular tissues and pathologies in knee osteoarthritis.
Osteoarthr Cartil Open. 2024 Jul 23;6(3):100505. doi: 10.1016/j.ocarto.2024.100505. eCollection 2024 Sep.
6
Effectiveness of methotrexate and bridging glucocorticoids with or without early introduction of a 6-month course of etanercept in early RA: results of the 2-year, pragmatic, randomised CareRA2020 trial.
RMD Open. 2024 Aug 7;10(3):e004535. doi: 10.1136/rmdopen-2024-004535.
7
Severity and progression of structural hand OA is not associated with progression of structural knee OA: The IMI-APPROACH cohort.
Osteoarthr Cartil Open. 2024 May 14;6(3):100487. doi: 10.1016/j.ocarto.2024.100487. eCollection 2024 Sep.
8
Determinants of radiographic progression in early psoriatic arthritis: insights from a real-world cohort.
RMD Open. 2024 May 24;10(2):e004080. doi: 10.1136/rmdopen-2024-004080.
9
Long-term clinical and radiological effectiveness and safety of ultralow doses of rituximab in rheumatoid arthritis: observational extension of the REDO trial.
RMD Open. 2024 Apr 9;10(2):e003659. doi: 10.1136/rmdopen-2023-003659.
10
Long-term efficacy of a 2-year MRI treat-to-target strategy on disease activity and radiographic progression in patients with rheumatoid arthritis in clinical remission: 5-year follow-up of the IMAGINE-RA randomised trial.
RMD Open. 2024 Mar 15;10(1):e003945. doi: 10.1136/rmdopen-2023-003945.
本文引用的文献
1
2
How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion.
Arthritis Rheum. 2002 Apr 15;47(2):215-8. doi: 10.1002/art.10181.
3
Smallest real difference, a link between reproducibility and responsiveness.
Qual Life Res. 2001;10(7):571-8. doi: 10.1023/a:1013138911638.
4
Measures of reliability in sports medicine and science.
Sports Med. 2000 Jul;30(1):1-15. doi: 10.2165/00007256-200030010-00001.
5
Reading radiographs in chronological order, in pairs or as single films has important implications for the discriminative power of rheumatoid arthritis clinical trials.
Rheumatology (Oxford). 1999 Dec;38(12):1213-20. doi: 10.1093/rheumatology/38.12.1213.
6
Assessing smallest detectable change over time in continuous structural outcome measures: application to radiological change in knee osteoarthritis.
J Clin Epidemiol. 1999 Dec;52(12):1225-30. doi: 10.1016/s0895-4356(99)00109-2.
7
Smallest detectable difference in radiological progression.
J Rheumatol. 1999 Mar;26(3):731-9.
8
Interpreting treatment effects in randomised trials.
BMJ. 1998 Feb 28;316(7132):690-3. doi: 10.1136/bmj.316.7132.690.
9
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.
Lancet. 1997 Aug 2;350(9074):309-18. doi: 10.1016/S0140-6736(97)01300-7.
10
Statistical methods for assessing agreement between two methods of clinical measurement.
Lancet. 1986 Feb 8;1(8476):307-10.
Zotero 插件